How Western National Interest Drives Ebola Drug Development

By Christopher Degeling, University of Sydney

Ebola virus disease typically only occurs in rural and remote areas among resource-poor populations. Until the large, recent outbreak in West Africa, cases of the illness were a rarity.

So the fact that we even have experimental drugs for the disease tells a story about how responses to global health crises are shaped by the social and political interests of the developed world.

Major pharmaceutical companies have shown little interest in developing effective treatments for diseases such as this. There’s no incentive for the commercial risks of research and companies naturally prefer to focus on diseases that can sustain large markets of wealthy regular users.

A similar inattention is suffered by people who have what are collectively known as neglected tropical diseases, which affect about a billion of the world’s poorest people.

They cause death and ill-health but also entrench social and political disadvantage. Even though most are preventable, and easily treatable with appropriate resources.

For those affected, the burden of these diseases, on average, equates to the loss of 56 years of healthy life through early death or chronic disability. Yet, the US Centers for Disease Control estimates that for 50 cents per year per person, the burden of neglected tropical diseases could be eliminated.

So it seems a little incongruous that drugs for Ebola virus disease were in development at all, given the relatively small number of cases and the poverty of those most at risk of infection.

Let’s consider the most advanced drug: ZMapp, which is produced by Mapp Biopharmaceuticals and is the experimental treatment the fuss has been about. The incentive for developing ZMapp was clearly not its broad commercial potential. Instead, it is for developing capacity for biodefence.

Bio-Threats on the Agenda

After the anthrax attacks of 2001 the US government launched project Bio-shield, a large-scale program aimed at developing organisational capacity and medical countermeasures to deal with existing and emerging biological threats to the US population.

Vast quantities of drugs and vaccines have been stockpiled by the Biomedical Advanced Research and Development Authority (BARDA). BARDA and the US military medical services have also partnered with hundreds of small biotechnology companies to develop medical countermeasures against pathogens that could potentially be used for bio-terrorism.

As well as ZMapp, BARDA is funding three other companies in the early stages of developing different countermeasures against Ebola virus disease.

Australia has benefited from this US military interest. The anti-serum against Hendra virus infection and the equine vaccine are the products of a coalition between the CSIRO and US military medical services.

Millions of dollars were spent on developing countermeasures for an Australian bat-borne pathogen that, as far as we know, has only killed four people. Horse-owners in Queensland have been slow to take up the vaccine, but the US military considers this research worth the investment.

Agents effective against Hendra are also likely to have protective effects against the related Nipah virus. Because of its potential for “weaponisation”, Nipah virus is classified as a likely bio-terrorism agent.

RECOMMENDED